RxDoctor Payments Data

Rodney Logan, MD

Family Medicine · Perry, NYNPI 1811989015

Payments from drug & device makers

$768in general payments, 2019–2025

Across 47 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$117
  • Amgen$77
  • Boehringer Ingelheim$76
  • Abbott$66
  • Dexcom, Inc.$60
  • Sanofi-aventis U.S. LLC$44
  • plus $328 from 12 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$768 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$4,435
Medicare patients
23
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$80,763
JardianceEmpagliflozin59$43,232
RybelsusSemaglutide29$34,745
FarxigaDapagliflozin Propanediol40$27,947
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr51$26,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,180
XareltoRivaroxaban15$22,020
OzempicSemaglutide11$15,678
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$15,478
LinzessLinaclotide13$10,770
MyrbetriqMirabegron12$10,202
JanuviaSitagliptin Phosphate25$9,580
Breo ElliptaFluticasone/Vilanterol20$7,935
Fiasp FlextouchInsulin Aspart (Niacinamide)15$6,633
GemtesaVibegron26$6,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$117$80,763119 claims
GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta$26$59,805105 claims
Novo NordiskRybelsus, Ozempic$38$50,42340 claims
Boehringer IngelheimJardiance$76$43,23259 claims
Johnson & JohnsonXarelto$14$22,02015 claims
AbbVieLinzess$36$10,77013 claims
Astellas Pharma US IncMyrbetriq$34$10,20212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Perry

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →